Gout

Uricase, Arthrobacter globiformis (Uox, Arthrobacter globiformis) is a uricase (urate oxidase) derived from Arthrobacter globiformis. Uricase, Arthrobacter globiformis converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, Arthrobacter globiformis can be used for research on chronic refractory gout and hyperuricemia.

Uricase, Bacillus fastidious (Uox, Bacillus fastidious) is a uricase (urate oxidase) derived from Bacillus fastidious. Uricase, Bacillus fastidious converts uric acid into allantoin. The absence of Uricase in mammals causes kidney diseases resulting from uric acid accumulation. Uricase, Bacillus fastidious can be used for research on chronic refractory gout and hyperuricemia.

GPR84 antagonist 9 is an orally active GPR84 antagonist with an IC₅₀ value of 12 nM. By antagonizing the GPR84 receptor, GPR84 antagonist 9 blocks immune cell migration, M1 polarization, and the release of inflammatory factors (IL1β/TNFα) induced by medium-chain free fatty acids (MCFFAs) and other substances, thereby comprehensively inhibiting inflammatory and fibrotic responses. GPR84 antagonist 9 can be used in the research of inflammation-driven pain disorders, including neuropathic pain disorders, Fabry disease, gout, and bladder pain syndrome.

Ulodesine succinate (BCX4208 succinate) is a purine nucleoside phosphorylase (PNP) inhibitor, with an IC₅₀ of 2.293 nM against human PNP, and low nanomolar IC₅₀ values against mouse, rat and monkey PNP. Ulodesine succinate blocks the production of uric acid precursors, reduces serum uric acid levels, clears accumulated uric acid in the blood, and elevates the levels of purine nucleosides including guanosine. Ulodesine succinate reduces the counts of total lymphocytes, T lymphocytes and lymphocyte subsets, inhibits the proliferation of cancer cells and activated lymphocytes, and enhances vaccine immune responses. Ulodesine succinate can be used in research related to hyperuricemia and gout.

G-25671 is a platelet cyclooxygenase (COX) inhibitor (K_i = 4.5 μM) and uricosuric agent, as well as the active metabolite of Sulfinpyrazone (HY-B1271). G-25671 reduces the production of thromboxane B₂ and malondialdehyde from arachidonic acid (AA), and inhibits human platelet aggregation induced by Sodium arachidonate (HY-109590A). G-25671 can be used in gout-related research.

HYJ-2 is a URAT1 inhibitor and urate-lowering agent. HYJ-2 inhibits URAT1-mediated urate transport and interacts with key residues within the URAT1 binding pocket. HYJ-2 reduces serum urate levels in hyperuricemic mice without inducing liver or kidney injury. HYJ-2 shows low cytotoxicity to hepatocytes and renal cells. HYJ-2 does not significantly induce hepatocyte apoptosis or mitochondrial dysfunction. HYJ-2 can be used in studies related to hyperuricemia and gout.

Xanthine oxidase-IN-22 is an orally active inhibitor of xanthine oxidase (XO) (IC₅₀: 0.0034 μM). Xanthine oxidase-IN-22 exhibits a mixed-type inhibition mode against XO. Xanthine oxidase-IN-22 reduces serum uric acid levels in mice. Xanthine oxidase-IN-22 can be used in research related to hyperuricemia and gout.